VANCOUVER, BC / ACCESSWIRE / March 6, 2017 / M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FRA: T3F2), (the "Company" or "M Pharma") announces that Kim Whittemore has been appointed to the Company's Board of Directors.
"Kim Whittemore provides M Pharma with extensive knowledge and expertise within the women's health space, a central focus of our business growth strategy," said Gary Thompson, M Pharma's President and CEO.
Kim Whittemore is a passionate advocate for women's health and sexual health. She has vast experience in the fields of digital health, wearable tech and women's health and through her management consulting practice, works with clients on business strategy and digital marketing. (Partial client list at kimwhit.com). Ms. Whittemore is a University of Pennsylvania International Relations graduate, completed MIT executive courses in Computer Science and has an advanced certificate in digital marketing. In her early career, Ms. Whittemore held senior executive positions with DecisionOne Corporation, Verizon and AT & T after beginning her career at the National Security Agency (NSA).
"As a C-Suite management consultant, Kim has developed and implemented go-to-market strategies in the healthcare space, and specifically within the women's health space, including the launch of a digital health service for infertility treatments. Her experience and negotiating skills, noting that she has secured an eight-figure licensing agreement with market leading companies, will be of great benefit to M Pharma," said Mr. Thompson. "Kim's experience and passion provide a great asset to our company and we are excited to have her join our team."
"As new members continue to join our Board, I would like to thank Mr. George Tsafalas for his tremendous leadership and guidance in serving M Pharma since its inception. George is resigning from the Board to make way for Kim, but will continue to support the Company as a senior business consultant," said Gary Thompson.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to C-103, a reformulation of orlistat, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field and has recently acquired a suite of products, the foundation of which is based on a patented and FDA cleared topical gel combining menthol & L-arginine. This innovative formulation can be paired with many different ingredients to address a multitude of medical issues, including a female dysfunction application that been submitted for patent protection.
M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."
"Kim Whittemore provides M Pharma with extensive knowledge and expertise within the women's health space, a central focus of our business growth strategy," said Gary Thompson, M Pharma's President and CEO.
Kim Whittemore is a passionate advocate for women's health and sexual health. She has vast experience in the fields of digital health, wearable tech and women's health and through her management consulting practice, works with clients on business strategy and digital marketing. (Partial client list at kimwhit.com). Ms. Whittemore is a University of Pennsylvania International Relations graduate, completed MIT executive courses in Computer Science and has an advanced certificate in digital marketing. In her early career, Ms. Whittemore held senior executive positions with DecisionOne Corporation, Verizon and AT & T after beginning her career at the National Security Agency (NSA).
"As a C-Suite management consultant, Kim has developed and implemented go-to-market strategies in the healthcare space, and specifically within the women's health space, including the launch of a digital health service for infertility treatments. Her experience and negotiating skills, noting that she has secured an eight-figure licensing agreement with market leading companies, will be of great benefit to M Pharma," said Mr. Thompson. "Kim's experience and passion provide a great asset to our company and we are excited to have her join our team."
"As new members continue to join our Board, I would like to thank Mr. George Tsafalas for his tremendous leadership and guidance in serving M Pharma since its inception. George is resigning from the Board to make way for Kim, but will continue to support the Company as a senior business consultant," said Gary Thompson.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to C-103, a reformulation of orlistat, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field and has recently acquired a suite of products, the foundation of which is based on a patented and FDA cleared topical gel combining menthol & L-arginine. This innovative formulation can be paired with many different ingredients to address a multitude of medical issues, including a female dysfunction application that been submitted for patent protection.
M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."
